|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CTSE |
Gene summary for CTSE |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CTSE | Gene ID | 1510 |
| Gene name | cathepsin E | |
| Gene Alias | CATE | |
| Cytomap | 1q32.1 | |
| Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | B4DNU8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1510 | CTSE | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.24e-15 | 9.96e-01 | -0.1808 |
| 1510 | CTSE | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.02e-17 | 6.41e-01 | -0.0811 |
| 1510 | CTSE | HTA11_78_2000001011 | Human | Colorectum | AD | 9.30e-13 | 7.57e-01 | -0.1088 |
| 1510 | CTSE | HTA11_411_2000001011 | Human | Colorectum | SER | 7.17e-13 | 1.87e+00 | -0.2602 |
| 1510 | CTSE | HTA11_696_2000001011 | Human | Colorectum | AD | 3.06e-09 | 3.11e-01 | -0.1464 |
| 1510 | CTSE | HCC2_Meng | Human | Liver | HCC | 1.30e-105 | 1.31e+00 | 0.0107 |
| 1510 | CTSE | S027 | Human | Liver | HCC | 9.18e-07 | 3.76e-01 | 0.2446 |
| 1510 | CTSE | S028 | Human | Liver | HCC | 2.23e-23 | 9.30e-01 | 0.2503 |
| 1510 | CTSE | S029 | Human | Liver | HCC | 7.07e-21 | 7.21e-01 | 0.2581 |
| 1510 | CTSE | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 2.24e-07 | 3.19e-01 | -0.2116 |
| 1510 | CTSE | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 2.39e-03 | -2.58e-01 | -0.0132 |
| 1510 | CTSE | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 9.44e-05 | -2.16e-01 | -0.013 |
| 1510 | CTSE | RNA-P7T1-P7T1-1 | Human | Lung | AIS | 7.75e-07 | 6.94e-01 | -0.0961 |
| 1510 | CTSE | RNA-P7T1-P7T1-2 | Human | Lung | AIS | 1.42e-06 | 6.05e-01 | -0.0876 |
| 1510 | CTSE | RNA-P7T1-P7T1-3 | Human | Lung | AIS | 2.18e-02 | 4.70e-01 | -0.0822 |
| 1510 | CTSE | RNA-P7T1-P7T1-4 | Human | Lung | AIS | 2.95e-03 | 3.06e-01 | -0.0809 |
| 1510 | CTSE | Pat01-B | Human | Stomach | GC | 2.81e-31 | -3.89e-01 | 0.5754 |
| 1510 | CTSE | Pat02-B | Human | Stomach | GC | 6.70e-45 | -6.13e-02 | 0.0368 |
| 1510 | CTSE | Pat03-B | Human | Stomach | GC | 3.51e-24 | -2.04e-01 | 0.3693 |
| 1510 | CTSE | Pat04-B | Human | Stomach | GC | 3.65e-33 | 1.27e-01 | -0.1483 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0051604 | Colorectum | AD | protein maturation | 85/3918 | 294/18723 | 6.73e-04 | 6.91e-03 | 85 |
| GO:0016485 | Colorectum | AD | protein processing | 63/3918 | 225/18723 | 6.77e-03 | 4.19e-02 | 63 |
| GO:00516041 | Colorectum | SER | protein maturation | 73/2897 | 294/18723 | 1.82e-05 | 5.38e-04 | 73 |
| GO:00164851 | Colorectum | SER | protein processing | 55/2897 | 225/18723 | 2.84e-04 | 4.67e-03 | 55 |
| GO:0048002 | Colorectum | SER | antigen processing and presentation of peptide antigen | 19/2897 | 62/18723 | 1.96e-03 | 1.97e-02 | 19 |
| GO:0019882 | Colorectum | SER | antigen processing and presentation | 28/2897 | 106/18723 | 2.52e-03 | 2.34e-02 | 28 |
| GO:005160412 | Liver | HCC | protein maturation | 171/7958 | 294/18723 | 3.80e-08 | 8.30e-07 | 171 |
| GO:001988212 | Liver | HCC | antigen processing and presentation | 65/7958 | 106/18723 | 7.06e-05 | 6.37e-04 | 65 |
| GO:000247811 | Liver | HCC | antigen processing and presentation of exogenous peptide antigen | 27/7958 | 38/18723 | 3.47e-04 | 2.42e-03 | 27 |
| GO:004800212 | Liver | HCC | antigen processing and presentation of peptide antigen | 40/7958 | 62/18723 | 3.84e-04 | 2.62e-03 | 40 |
| GO:001648511 | Liver | HCC | protein processing | 121/7958 | 225/18723 | 4.01e-04 | 2.71e-03 | 121 |
| GO:001988611 | Liver | HCC | antigen processing and presentation of exogenous peptide antigen via MHC class II | 22/7958 | 30/18723 | 6.14e-04 | 3.82e-03 | 22 |
| GO:001988411 | Liver | HCC | antigen processing and presentation of exogenous antigen | 31/7958 | 47/18723 | 9.90e-04 | 5.71e-03 | 31 |
| GO:000250411 | Liver | HCC | antigen processing and presentation of peptide or polysaccharide antigen via MHC class II | 24/7958 | 36/18723 | 2.95e-03 | 1.38e-02 | 24 |
| GO:000249511 | Liver | HCC | antigen processing and presentation of peptide antigen via MHC class II | 22/7958 | 34/18723 | 7.46e-03 | 2.96e-02 | 22 |
| GO:00198867 | Lung | IAC | antigen processing and presentation of exogenous peptide antigen via MHC class II | 10/2061 | 30/18723 | 9.63e-04 | 1.16e-02 | 10 |
| GO:00025046 | Lung | IAC | antigen processing and presentation of peptide or polysaccharide antigen via MHC class II | 11/2061 | 36/18723 | 1.23e-03 | 1.42e-02 | 11 |
| GO:00024788 | Lung | IAC | antigen processing and presentation of exogenous peptide antigen | 11/2061 | 38/18723 | 2.00e-03 | 2.01e-02 | 11 |
| GO:00024956 | Lung | IAC | antigen processing and presentation of peptide antigen via MHC class II | 10/2061 | 34/18723 | 2.79e-03 | 2.52e-02 | 10 |
| GO:00198848 | Lung | IAC | antigen processing and presentation of exogenous antigen | 12/2061 | 47/18723 | 4.05e-03 | 3.31e-02 | 12 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04142 | Colorectum | SER | Lysosome | 38/1580 | 132/8465 | 2.87e-03 | 2.03e-02 | 1.47e-02 | 38 |
| hsa041421 | Colorectum | SER | Lysosome | 38/1580 | 132/8465 | 2.87e-03 | 2.03e-02 | 1.47e-02 | 38 |
| hsa041422 | Liver | HCC | Lysosome | 100/4020 | 132/8465 | 2.32e-11 | 4.31e-10 | 2.40e-10 | 100 |
| hsa041423 | Liver | HCC | Lysosome | 100/4020 | 132/8465 | 2.32e-11 | 4.31e-10 | 2.40e-10 | 100 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CTSE | SNV | Missense_Mutation | rs782358758 | c.628G>C | p.Val210Leu | p.V210L | P14091 | protein_coding | tolerated(0.15) | probably_damaging(0.968) | TCGA-A8-A09M-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | CR |
| CTSE | SNV | Missense_Mutation | novel | c.813C>A | p.Phe271Leu | p.F271L | P14091 | protein_coding | tolerated(0.54) | possibly_damaging(0.859) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CTSE | insertion | Frame_Shift_Ins | novel | c.360_361insATTAATATATGTTATATAATATATAATATATT | p.Gln121IlefsTer49 | p.Q121Ifs*49 | P14091 | protein_coding | TCGA-A8-A06O-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | letrozole | SD | ||
| CTSE | insertion | Nonsense_Mutation | novel | c.814_815insCAGCCCTACCCCTAAGCCTCTATTAACTCCTTCCCAAA | p.Cys272SerfsTer9 | p.C272Sfs*9 | P14091 | protein_coding | TCGA-BH-A0HU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD | ||
| CTSE | SNV | Missense_Mutation | c.646T>C | p.Ser216Pro | p.S216P | P14091 | protein_coding | deleterious(0) | probably_damaging(0.942) | TCGA-EA-A3HT-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CTSE | SNV | Missense_Mutation | novel | c.934N>C | p.Val312Leu | p.V312L | P14091 | protein_coding | tolerated(0.07) | benign(0.085) | TCGA-AA-3950-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CTSE | SNV | Missense_Mutation | c.55G>A | p.Gly19Arg | p.G19R | P14091 | protein_coding | tolerated(0.48) | benign(0.031) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| CTSE | SNV | Missense_Mutation | novel | c.451N>A | p.Asp151Asn | p.D151N | P14091 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
| CTSE | deletion | Frame_Shift_Del | novel | c.1021delN | p.Leu341TyrfsTer71 | p.L341Yfs*71 | P14091 | protein_coding | TCGA-F4-6570-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| CTSE | SNV | Missense_Mutation | novel | c.638N>T | p.Pro213Leu | p.P213L | P14091 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 1510 | CTSE | DRUGGABLE GENOME, PROTEASE, ENZYME | inhibitor | 178103180 | ||
| 1510 | CTSE | DRUGGABLE GENOME, PROTEASE, ENZYME | inhibitor | 252166834 | ||
| 1510 | CTSE | DRUGGABLE GENOME, PROTEASE, ENZYME | inhibitor | 252166874 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |